Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis Pharmaceuticals
Biotech
Arrowhead on target in lipid disorder as it pursues Ionis
Arrowhead linked its RNAi drug candidate to improved outcomes through Week 48 to stay on Ionis’ tail in the race to market.
Nick Paul Taylor
Apr 8, 2024 9:37am
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
Mar 13, 2024 9:54am
Ionis’ HAE drug wins in phase 3 setting up approval run to FDA
Jan 22, 2024 9:34am
Otsuka pays Ionis $65M for European rights to rare disease drug
Dec 19, 2023 10:18am
AstraZeneca adds Latin America to Ionis ATTR deal for $20M
Jul 28, 2023 10:05am
Ionis' midphase misses send rare disease prospects to the abyss
May 4, 2023 10:25am